Application No. 09/762.893 Attorney Docket No. 02481.1734-00

in which

 R^1 is (C_1-C_8) -alky, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C_1-C_4) -alkoxy, (C_1-C_4) -alkyl-S $(O)_m$ -, R⁵R⁶N and arxl; (C₃-C₉)-cycloalkyl, which can be substituted by one or more identical ox different substituents chosen from (C1-C4)-alkyl, hydroxyl and amino; or a radical of a 5-membered to 7-membered saturated heterocyclic ring that contains one or two identical or different hetero ring members chosen from O, NR7 and S(O)_m and that can be substituted by one or more identical of different substituents chosen from (C₁-C₄)-alkyl and aryl- (C_1-C_4) -alkyl-;

and

R² is hydrogen, (C₁-C₈)-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)alkyl-S(O)_m-, R⁵R⁶N and aryl; (C₃-C₉)-cycloalkyl, which can be substituted by one or more identical or different\substituents chosen from (C₁-C₄)alkyl, hydroxyl and amino; or the radical of a 5-membered to 7-membered saturated heterocyclic ring that contains one or two identical or different hetero ring members chosen from O, NR⁷ and S(O)_m and that can be substituted by one or more identical or different substituents chosen from (C_1-C_4) -alkyl and aryl- (C_1-C_4) -alkyl-; or

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

R¹R²N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated heterocyclic ring that, in addition to the nitrogen atom carrying the radicals R¹ and R², can contain a further hetero ring member chosen from O, NR⁷ and S(O)_m and that can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl, \(C₁-C₄\)-alkoxy, R⁸R⁹N, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl and R8R9N-CO-:

R³ is phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, (C1-C4)-alkyl, phenyl, CF3, NO2, OH, - $O-(C_1-C_4)$ -alkyl, $-O(C_2-C_4)$ -alkyl- $O-(C_1-C_4)$ -alkyl, (C_1-C_2) -alkylenedioxy, NH_2 , $-NH-(C_1-C_4)-alkyl$, $N((C_1-C_4)-alkyl)_2$, -NH-CHO, $-NH-CO-(C_1-C_4)-alkyl$ alkyl, -CN, -CO-NH₂, - \CO -NH-(C₁-C₄)-alkyl, -CO-N((C₁-C₄)-alkyl)-₂, -CO-OH, -CO-O-(C_1 - C_4)-alkyl, -CHO and -CO-(C_1 - C_4)-alkyl;

R⁴ is (C₂-C₅)-alkyl, trifluoromethyl of phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, (C₁-C₄)-alkyl, phenyl, CF_3 , NO_2 , OH, $-O-(C_1-\dot{C}_4)$ -alkyl, $-O-(C_2-C_4)$ -alkyl- $O-(C_1-C_4)$ -alkyl, (C_1-C_2) -alkylenedioxy, NH_2 , $-NH-(C_1-C_4)$ -alkyl, $N((C_1-C_4)$ -alkyl₂, -NH-CHO, -NH-CO-(C_1 - C_4)-alkyl, -CN, -CO-N H_2 , -CO-NH-(C_1 - C_4)-alkyl, -CO-N((C_1 - C_4)-alkyl₂, -CO-OH, -CO-O-(C_1 - C_4)- $\frac{1}{2}$ alkyl, -CHO and -CO-(C_1 - C_4)-alkyl;

R⁵ and R⁶ are identical or different radicals chosen from hydrogen and (C₁-C₄)alkyl; or the group R⁵R⁶N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated on unsaturated heterocyclic ring that, in addition to the nitrogen atom carrying the radicals R⁵ and R⁶, can additionally contain as a further hetero ring member an oxygen atom, a group S(O)_m or a nitrogen atom and that can carry on ring carbon atoms

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

one or more identical or different substituents chosen from (C_1-C_4) -alkyl, hydroxyl and amino and that can carry on a ring nitrogen atom a radical R^7 ;

 R^7 is hydrogen, (C_1-C_4) -alkyl, aryl- (C_1-C_4) -alkyl-, hydroxy- (C_1-C_4) -alkyl, hydroxycarbonyl- (C_1-C_4) -alkyl-, $((C_1-C_4)$ -alkoxycarbonyl)- (C_1-C_4) -alkyl, R^8R^9N -CO- (C_1-C_4) -alkyl-, R^{10} -SO₂- or aryl; where R^7 , if this group is present on a piperazino radical representing R^1R^2N , cannot be carbocyclic aryl or carbocyclic aryl- (C^1-C^4) -alkyl;

R⁸ and R⁹ are identical or different radicals chosen from hydrogen and (C₁-C₄)-alkyl;

 R^{10} is (C_1-C_4) -alkyl, aryl or $R^8R^{\flat}N$;

aryl is phenyl, naphthyl or heteroaryl, all of which can be substituted by one or more identical or different substituents chosen from halogen, (C_1-C_4) -alkyl, phenyl, CF_3 , NO2, OH, $-O-(C_1-C_4)$ -alkyl, $O-(C_2-C_4)$ -alkyl- $O-(C_1-C_4)$ -alkyl, (C_1-C_2) -alkylenedioxy, NH_2 , $-NH_1$ - (C_1-C_4) -alkyl, $-N((C_1-C_4)$ -alkyl, $-N((C_1-C_4$

heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or of a bicyclic 8-membered to 10-membered aromatic

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

heterocycle, each of which contains one or more identical or different ring heteroatoms chosen from N, O and S;

m is 0, 1 or 2;

or a stereoisomeric form of a compound of formula I,

or a mixture of stereoisomeric forms of compounds of formula I in all ratios,

or a physiologically tolerable salt of a compound of formula I,

or a physiologically tolerable salt of a stereoisomeric form of a compound of formula I;

X

compounds of the formula I being excluded in which, simultaneously, R^4 is ethyl, tert-butyl, or trifluoromethyl; R^3 is phenyl, which can be substituted by one or two identical or different substituents chosen from halogen, OH, -O- R^{11} and CF₃, R^1R^2N is R^{11} -NH-, $(R^{11})_2N$ - or $R^{12}R^{13}N$ -(CH₂)_p-NH-; p is 2 or 3; R^{11} is saturated unsubstituted (C₁-C₄)-alkyl; and R^{12} and R^{13} are identical or different radicals chosen from hydrogen and R^{11} or the group $R^{12}R^{13}N$ is a radical, bonded via a ring nitrogen atom, of a 5-membered or 6-membered saturated heterocyclic ring that, in addition to the nitrogen atom carrying the radicals R^{12} and R^{13} , can additionally contain as a further hetero ring member an oxygen atom, a sulfur atom or a nitrogen atom and that can be substituted by an aryl substituted by one or two identical or different substituents chosen from halogen, OH, -O- R^{11} , and CF₃.

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP


1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com 15. A process for the preparation of at least one compound of claim 5, which comprises activating a 4-hydroxypyrimidine of the formula IV and then reacting it with an amine of a formula VI;

50h 194 50b

and optionally reacting the resulting product with a suitable reagent to form a pharmaceutically acceptable salt.

22. A method of treating a cardiovascular disorder, comprising administering to a patient in need thereof an effective amount of at least one compound of formula.

5 ub D5



in which

 R^1 is (C_1-C_8) -alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C_1-C_4) -alkoxy, (C_1-C_4) -alkyl- $S(O)_m$ -, R^5R^6N and aryl; (C_3-C_9) -cycloalkyl, which can be substituted by one or more identical or different substituents chosen from (C_1-C_4) -alkyl, hydroxyl and amino; or a radical of a 5-membered to 7-membered saturated heterocyclic ring that contains one or two identical or different hetero ring members chosen from O, NR^7 and $S(O)_m$ and that can be substituted by one or more identical or different substituents chosen from (C_1-C_4) -alkyl and aryl- (C_1-C_4) -alkyl-;

and

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com R^2 is hydrogen, (C₁-C₈)-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C₁-C₄)-alkoxy, (C₁-C₄)-alkyl-S(O)_m-, R^5R^6N and aryl; (C₃-C₉)-cycloalkyl, which can be substituted

by one or more identical or different substituents chosen from (C_1-C_4) -alkyl, hydroxyl and amino; or the radical of a 5-membered to 7-membered saturated heterocyclic ring that contains one or two identical or different hetero ring members chosen from O, NR⁷ and S(O)_m and that can be substituted by one or more identical or different substituents chosen from (C_1-C_4) -alkyl and aryl- (C_1-C_4) -alkyl-; or

Sub

R¹R²N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated heterocyclic ring that, in addition to the nitrogen atom carrying the radicals R¹ and R², can contain a further hetero ring member chosen from O, NR⁷ and S(O)_m and that can be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl, (C₁-C₄)-alkoxy, R⁸R⁹N, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl and R⁸R⁹N-CO-:

(3

 R^3 is phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, (C₁-C₄)-alkyl, phenyl, CF₃, NO₂, OH, - O-(C₁-C₄)-alkyl, -O-(C₂-C₄)-alkyl-O-(C₁-C₄)-alkyl, (C₁-C₂)-alkylenedioxy, NH₂, -NH-(C₁-C₄)-alkyl, N((C₁-C₄)-alkyl)₂, -NH-CHO, -NH-CO-(C₁-C₄)-alkyl, -CN, -CO-NH₂, -CO-NH-(C₁-C₄)-alkyl, -CO-N((C₁-C₄)-alkyl)₋₂, -CO-OH, -CO-O-(C₁-C₄)-alkyl, -CHO and -CO-(C₁-C₄)-alkyl;

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202,408.4000 Fax 202.408.4400 www.finnegan.com R⁴ is (C₂-C₅)-alkyl, trifluoromethyl or phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, (C₁-C₄)-alkyl, phenyl, CF₃, NO₂, OH, -O-(C₁-C₄)-alkyl, -O-(C₂-C₄)-alkyl-O-(C₁-C₄)-alkyl, (C₁-C₂)-alkylenedioxy, NH₂, -NH-(C₁-C₄)-alkyl, N((C₁-C₄)-alkyl₂, -NH-CHO, -NH-CO-(C₁-C₄)-alkyl, -CN, -CO-NH₂, -CO-NH-(C₁-C₄)-alkyl, -CO-N((C₁-C₄)-alkyl₂, -CO-OH, -CO-O-(C₁-C₄)-alkyl, -CHO and -CO-(C₁-C₄)-alkyl;

R⁵ and R⁶ are identical or different radicals chosen from hydrogen and (C₁-C₄)-alkyl; or the group R⁵R⁶N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated or unsaturated heterocyclic ring that, in addition to the nitrogen atom carrying the radicals R⁵ and R⁶, can additionally contain as a further hetero ring member an oxygen atom, a group S(O)_m or a nitrogen atom and that can carry on ring carbon atoms one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl and amino and that can carry on a ring nitrogen atom a radical R⁷:

 θ^{5}

es

 R^7 is hydrogen, (C_1-C_4) -alkyl, aryl- (C_1-C_4) -alkyl-, hydroxy- (C_1-C_4) -alkyl, hydroxycarbonyl- (C_1-C_4) -alkyl-, $((C_1-C_4)$ -alkoxycarbonyl)- (C_1-C_4) -alkyl, R^8R^9N -CO- (C_1-C_4) -alkyl-, R^{10} -SO₂- or aryl; where R^7 , if this group is present on a piperazino radical representing R^1R^2N , cannot be carbocyclic aryl or carbocyclic aryl- (C^1-C^4) -alkyl;

R⁸ and R⁹ are identical or different radicals chosen from hydrogen and (C₁-C₄)-alkyl;

 R^{10} is (C_1-C_4) -alkyl, aryl or R^8R^9N ;

aryl is phenyl, naphthyl or heteroaryl, all of which can be substituted by one or more identical or different substituents chosen from halogen, (C₁-C₄)-alkyl, phenyl, CF₃, NO2, OH, -O-(C₁-C₄)-alkyl, O-(C₂-C₄)-alkyl-O-(C₁-C₄)-alkyl, (C₁-C₂)-alkylenedioxy, NH₂, -NH-(C₁-C₄)-alkyl, -N((C₁-C₄)-alkyl, -NH-CO-(C₁-C₄)-alkyl, -CO-NH-(C₁-C₄)-alkyl, -

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

Application No. 09/762,893 Attorney Docket No. 02481.1734-00

 $N((C_1-C_4)-alkyl_2, -CO-OH, -CO-O-(C_1-C_4)-alkyl, -CHO and -CO-(C_1-C_4)-alkyl;$

Sub 05

heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or of a bicyclic 8-membered to 10-membered aromatic heterocycle, each of which contains one or more identical or different ring heteroatoms chosen from N, O and S;

m is 0, 1 or 2;

or a stereoisomeric form of a compound of formula I,
or a mixture of stereoisomeric forms of compounds of formula I in all ratios,
or a physiologically tolerable salt of a compound of formula I,
or a physiologically tolerable salt of a stereoisomeric form of a compound of
formula I.

Status of the claims

Claims 1-8, 10-15, and 17-23 are pending in this application. Claims 1 and 2 have been amended to correct a typographical error in the definition of the radical R⁵R⁶N, replacing the second appearance of the word "saturated" with "unsaturated." Support for this amendment can be found in the specification at page 5, line 16. Claim 15 has been amended to more clearly define the subject matter of the invention.

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP